- Home
- MCRB
MCRB
Seres Therapeutics Inc.
as 12-20-2024 4:00pm EST
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 2015 |
| Target Price: | $5.63 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $2.05 | Next Earning Date: | 11-13-2024 |
| Revenue: | $126,325,000 | Revenue Growth: | 12856.41% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Seres Therapeutics Inc. (MCRB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Teresa L. | MCRB | See Remarks | Nov 15 '24 | Sell | $0.54 | 735 | $397.64 | 90,404 | |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | Nov 15 '24 | Sell | $0.54 | 878 | $474.73 | 135,192 | |
| von Moltke Lisa | MCRB | See Remarks | Nov 15 '24 | Sell | $0.54 | 977 | $528.26 | 32,415 | |
| Shaff Eric D. | MCRB | CEO and President | Nov 15 '24 | Sell | $0.54 | 2,505 | $1,354.95 | 170,389 | |
| Henn Matthew R. | MCRB | See Remarks | Nov 15 '24 | Sell | $0.54 | 927 | $501.23 | 77,770 | |
| Young Teresa L. | MCRB | See Remarks | Oct 27 '24 | Sell | $0.69 | 2,983 | $2,058.57 | 90,404 | |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | Oct 27 '24 | Sell | $0.69 | 4,259 | $2,939.14 | 135,192 | |
| von Moltke Lisa | MCRB | See Remarks | Oct 27 '24 | Sell | $0.69 | 4,334 | $2,991.33 | 32,415 | |
| Shaff Eric D. | MCRB | CEO and President | Oct 27 '24 | Sell | $0.69 | 8,748 | $6,036.99 | 170,389 | |
| Henn Matthew R. | MCRB | See Remarks | Oct 27 '24 | Sell | $0.69 | 3,984 | $2,749.36 | 77,770 |
Latest Seres Therapeutics Inc. News
MCRB Breaking Stock News: Dive into MCRB Ticker-Specific Updates for Smart Investing
TipRanks
4 days ago
Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference
GlobeNewswire
5 days ago
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
Pharmaceutical Technology
11 days ago
Seres’ SER-155 gains breakthrough status for BSIs reduction
MT Newswires
12 days ago
Seres Therapeutics Says FDA Grants Breakthrough Therapy Status to SER-155
GlobeNewswire
12 days ago
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
GlobeNewswire
a month ago
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Simply Wall St.
a month ago
Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)
GuruFocus.com
a month ago
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...
Compare MCRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MCRB Seres Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.